Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of thyroid disorders
3.2.1.2 Technological advancements in drug formulations
3.2.1.3 Increasing healthcare expenditure
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and complications of treatment
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Levothyroxine
5.3 Liothyronine
5.4 Propylthiouracil
5.5 Imidazole-based compounds
5.6 Beta-blockers
5.7 Other drug types
Chapter 6 Market Estimates and Forecast, By Disease, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Hypothyroidism
6.3 Hyperthyroidism
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Intravenous
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Wholesalers/distributors
8.3 Retail chain
8.4 Online distribution
8.5 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 AbbVie Inc.
10.3 Aspen Pharmacare Holdings Limited
10.4 Glenmark Pharmaceuticals Ltd.
10.5 Lannett Company, Inc.
10.6 Merck & Co., Inc.
10.7 Mylan N.V.
10.8 Novartis AG
10.9 Pfizer Inc.
10.10 Sun Pharmaceutical Industries Limited
